Erik Haas, worldwide VP of litigation, Johnson & Johnson said: “We will immediately appeal this egregious and patently unconstitutional verdict that is the direct result of the gross errors made by the trial court that allowed plaintiff’s counsel to pervade the record with improper and prejudicial statements and assertions. The verdict is squarely at odds- in result and amount-with the vast majority of other talc cases wherein the Company has prevailed and expect the appellate court to reverse the verdict. These lawsuits are predicated on “junk science,” refuted by decades of studies, that demonstrate Johnson’s Baby Powder is safe, does not contain asbestos and does not cause cancer. The Company will continue to advocate for gold standard science in the U.S. judicial system. For far too long American juries have been permitted to review junk science supporting plaintiff lawyers in search of jackpot verdicts, instead of science from scientific agencies authorized by Congress to evaluate such matters.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson (JNJ) Faces $1.56 Billion Blow in Asbestos Lawsuit
- Government deals lift overhang on pharma group, says BofA
- Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
- Johnson & Johnson announces FDA approval of TRUFILL n-BCA Liquid Embolic System
- Johnson & Johnson price target raised to $240 from $213 at Goldman Sachs
